4.5 Article

Patterns of pharmacological maintenance treatment in a community mental health services bipolar disorder cohort study (SIN-DEPRES)

Journal

INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
Volume 16, Issue 3, Pages 513-523

Publisher

OXFORD UNIV PRESS
DOI: 10.1017/S1461145712000405

Keywords

Bipolar disorder; community mental health services; cross-sectional studies; drug therapy

Funding

  1. Hospital Clinic de Barcelona (HCB)
  2. GlaxoSmithKline
  3. S.A. Tres Cantos, Madrid, Spain
  4. Almirall
  5. AstraZeneca
  6. Bristol-Myers Squibb
  7. Eli Lilly
  8. Janssen-Cilag
  9. Novartis
  10. Pfizer Inc
  11. Sanofi-Aventis
  12. Servier
  13. Spanish Ministry of Health
  14. Bristol
  15. UCB Pharma
  16. Boehringer Ingelheim
  17. Bristol-Myers-Squibb
  18. Bial
  19. Forest Research Institute
  20. Gedeon Richter
  21. Jazz
  22. MSD
  23. Organon
  24. Otsuka
  25. Pierre-Fabre
  26. Solvay
  27. UBC
  28. Wyeth
  29. Spanish Ministry of Science and Education
  30. Stanley Medical Research Institute
  31. European Union

Ask authors/readers for more resources

Maintenance therapy in bipolar disorder (BD) is usually required to prevent relapses and improve residual symptoms. Therefore, in this study, we describe patterns of pharmacological maintenance treatment and identify associated clinical features. This prospective multicentre epidemiological study recruited a cohort of 739 consecutive out-patients with clinically stable BD. Clinical stability was assessed at baseline with the Clinical Global Impression scale for BD and depressive symptoms with the Hamilton Depression Rating Scale. Psychotropic medications were classified and analysed according to their mechanism as well as use. Logistic regression models were used to examine the associations between pharmacological strategies and clinical features. Longer time since last episode [odds ratio (OR) 1.002, p<0.0001] and family history of psychiatric disorders (OR 1.911, p=0.028) were associated with lithium in monotherapy; manic polarity of the most recent episode (OR 3.300, p=0.006) and longer duration of clinical stability (OR 1.009, p=0.034) with antipsychotic in monotherapy; depressive polarity of the most recent episode (OR 2.567, p=0.003) and bipolar II disorder diagnosis (OR 2.278, p=0.008) with antidepressant combination; no ongoing psychiatric co-morbidity (OR 0.230, p=0.004) with lithium and anticonvulsant; manic polarity of the most recent episode (OR 3.774, p<0.0001) with lithium and antipsychotic; manic polarity of the most recent episode (OR 2.907, p=0.028) with lithium, anticonvulsant and antipsychotic. The pharmacological patterns followed published recommendations, except for the excessive use of antidepressants. This study reveals clinical factors closely related to prescription patterns.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available